S
Srinivasan Venkatramanan
Researcher at University of Virginia
Publications - 77
Citations - 2285
Srinivasan Venkatramanan is an academic researcher from University of Virginia. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 12, co-authored 63 publications receiving 1523 citations. Previous affiliations of Srinivasan Venkatramanan include The Chinese University of Hong Kong & Indian Institute of Science.
Papers
More filters
Journal ArticleDOI
Commentary on Ferguson, et al., "Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand".
Stephen Eubank,I. Eckstrand,Bryan Lewis,Srinivasan Venkatramanan,Madhav V. Marathe,Christopher L. Barrett +5 more
TL;DR: A coarse taxonomy of models is discussed and the context and significance of the Imperial College and other models in contributing to the analysis of COVID-19 are explored.
Journal ArticleDOI
Using data-driven agent-based models for forecasting emerging infectious diseases.
Srinivasan Venkatramanan,Bryan Lewis,Jiangzhuo Chen,Dave Higdon,Dave Higdon,Anil Vullikanti,Anil Vullikanti,Madhav V. Marathe,Madhav V. Marathe +8 more
TL;DR: This paper describes one such agent-based model framework developed for forecasting the 2014-2015 Ebola epidemic in Liberia, and subsequently used during the Ebola forecasting challenge, and concludes by highlighting how such a data-driven approach can be refined and adapted for future epidemics.
Journal ArticleDOI
Mathematical Models for COVID-19 Pandemic: A Comparative Analysis.
Aniruddha Adiga,Devdatt Dubhashi,Bryan Lewis,Madhav V. Marathe,Srinivasan Venkatramanan,Anil Vullikanti +5 more
TL;DR: This article reviews some of the important mathematical models used to support the ongoing planning and response efforts in the COVID-19 pandemic and discusses their use, their mathematical form and their scope.
Journal ArticleDOI
Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios - United States, April-September 2021.
Rebecca K. Borchering,Cécile Viboud,Emily Howerton,Claire P. Smith,Shaun A. Truelove,Michael C. Runge,Nicholas G. Reich,Lucie Contamin,John Levander,Jessica Salerno,Willem G. van Panhuis,Matt Kinsey,Kate Tallaksen,R. Freddy Obrecht,Laura Asher,Cash Costello,Michael Kelbaugh,Shelby Wilson,Lauren Shin,Molly E. Gallagher,Luke C. Mullany,Kaitlin Rainwater-Lovett,Joseph C. Lemaitre,Juan Dent,Kyra H. Grantz,Joshua Kaminsky,Stephen A. Lauer,Elizabeth C. Lee,Hannah R. Meredith,Javier Perez-Saez,Lindsay T Keegan,Lindsay T Keegan,D. Karlen,Matteo Chinazzi,Jessica T. Davis,Kunpeng Mu,Xinyue Xiong,Ana Pastore y Piontti,Alessandro Vespignani,Ajitesh Srivastava,Przemyslaw J. Porebski,Srinivasan Venkatramanan,Aniruddha Adiga,Bryan Lewis,Brian D. Klahn,Joseph Outten,James Schlitt,Patrick Corbett,Pyrros A Telionis,Lijing Wang,Akhil Sai Peddireddy,Benjamin Hurt,Jiangzhuo Chen,Anil Vullikanti,Madhav V. Marathe,Jessica M. Healy,Rachel B. Slayton,Matthew Biggerstaff,Michael A. Johansson,Katriona Shea,Justin Lessler +60 more
TL;DR: In this paper, the authors used a multiple-model approach comprising six models to assess the potential course of COVID-19 in the United States across four scenarios with different vaccination coverage rates and effectiveness estimates and strength and implementation of nonpharmaceutical interventions (NPIs) (such as physical distancing and masking) over a 6-month period (April-September 2021) using data available through March 27, 2021 (4).
Journal ArticleDOI
A framework for evaluating epidemic forecasts
Farzaneh Sadat Tabataba,Farzaneh Sadat Tabataba,Prithwish Chakraborty,Naren Ramakrishnan,Naren Ramakrishnan,Srinivasan Venkatramanan,Jiangzhuo Chen,Bryan Lewis,Madhav V. Marathe,Madhav V. Marathe +9 more
TL;DR: This paper presents an evaluation framework which allows for combining different features, error measures, and ranking schema to evaluate forecasts, and demonstrates the utility of the framework by evaluating six forecasting methods for predicting influenza in the United States.